Mode
Text Size
Log in / Sign up
N/A N=212 Randomized Double-blind Diagnostic

Study of Efficacy and Tolerability of Various Bowel Preps in Diabetic Patients

Diabetes Mellitus

Enrolled (actual)
212
Serious AEs
0.0%
Results posted
Aug 2018
Primary outcome: Primary: Measure the % of Participants With Effective (How Well the Colon is Cleansed Using the Validated Boston Bowel Preparation Scale) for Various Bowel Preparations for Colonoscopy. — 42; 50; 47 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Golytely (polyethylene glycol electrolyte lavage solution) and placebo (Drug); split dose of Golytely (polyethylene glycol electrolyte lavage solution) + placebo (Drug); split dose of Golytely (polyethylene glycol electrolyte lavage solution) and bisacodyl (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Oklahoma
Primary completion
Oct 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Measure the % of Participants With Effective (How Well the Colon is Cleansed Using the Validated Boston Bowel Preparation Scale) for Various Bowel Preparations for Colonoscopy.
42; 50; 47
SECONDARY
Measure of Patients Who Develop (Tolerance)Side Effects of Taking Bowel Preparations.
24; 28; 28

Summary

Poor bowel preparation and patient intolerance of the procedure are the most important factors contributing to the limitation of colonoscopy. Inadequate bowel cleansing results in incomplete testing, increased potential to miss lesions, increased cost, and decreased patient satisfaction. The investigators hope to gain better insight into which bowel preparation works best in diabetic patients and hence would increase patient satisfaction, tolerability of the bowel preparation and decrease overall costs. The investigators will investigate which bowel preparation for colonoscopy will work optimally in diabetic patients using three different regimens.

Eligibility Criteria

Inclusion Criteria

  • adult diabetic outpatients referred for elective colonoscopy

Exclusion Criteria

  • patients 75 yrs of age,
  • known or suspected pregnancy,
  • known or suspected renal failure,
  • unstable angina,
  • acute coronary syndrome,
  • decompensated congestive heart failure,
  • decompensated liver failure,
  • known or suspected bowel obstruction,
  • major psychiatric illness,
  • solid organ transplant patients,
  • known allergies to PEG-ELS or bisacodyl,
  • prior alimentary tract surgery or refusal to consent to the study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01533688). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search